TP53 mutation, allelism and survival in non-small cell lung cancer

Carcinogenesis

Volumn 26, Issue 10, 2005, Pages 1770-1773

  Nelson, Heather ^a   Wilkojmen, Magnus ^a   Marsit, Carmen J ^a   Kelsey, Karl T ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ALLELISM; ARTICLE; CANCER SURVIVAL; CASE STUDY; CODON; CONTROLLED STUDY; FEMALE; GENE LOCATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SELECTION; GENOTYPE; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; AMINO ACID SUBSTITUTION; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27144545357     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi125     Document Type: Article

References (19)

1. Marin, M., Jost, C., Brooks, L. et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet., 25, 47-54.
2. Gaiddon, C., Lakshin, M., Ahn, J., Zhang, T. and Prives, C. (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol., 21, 1974-1887.
3. Strano, S., Fontemaggi, G., Costanzo, A. et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem., 277, 18817-18826.
4. Tada, M., Furuuchi, K., Kaneda, M., Matsumoto, J., Takahashi, A., Hirai, A., Mitsumoto, Y., Iggo, R.D. and Moriuchi, T. (2001) Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis, 22, 515-517.
5. Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L,. and Matlashewski, G. (1999) Two polymorphic variant of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol., 19, 1092-1100.
6. Bergamaschi, D., Gasco, M., Hiller, L. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via polymorphism of p73-dependent apoptosis. Cancer Cell, 3, 387-402.
7. Brooks, L., Tidy, J.A., Gusterson, B., Hiller, L., O'Nions, J., Gasco, M., Marin, M.C., Farrell, P.J., Kaelin, W.G. and Crook, T. (2000) Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res., 60, 6875-6877.
8. Furihata, M., Takeuchi, T., Matsumoto, M., Kurabayashi, A., Ohtsuki, Y., Terao, N., Kuwahara, M. and Shuin, T. (2002) p53 mutation arising in Arg72 allele in tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res., 8, 1192-1195.
9. Schneider-Stock, R., Mawrin, C., Motsch, C. et al. (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am. J. Pathol., 164, 1233-1241.
10. McGregor, J., Harwood, C.A., Brooks, L. et al. (2002) Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J. Invest. Dermatatol., 119, 84-90.
11. Nelson, H.H., Christiani, D.C., Mark, E.J., Wiencke, J.K., Wain, J.C. and Kelsey, K.T. (1999) Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J. Natl Cancer Inst., 91, 2032-2018.
12. Nelson, H.H., Wiencke, J.K., Gunn, L., Wain, J.C., Christiani, D.C. and Kelsey, K.T. (1998) Chromosome 3p14 alterations in lung cancer: Evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res., 58, 1804-1807.
13. Toguchida, J., Yamaguchi, T., Ritchie, B. et al. (1992) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res., 52, 6194-6199.
14. Ara, S., Lee, P.S., Hansen, M.F. and Saya, H. (1990) Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res., 18, 4961.
15. Mehdi, S.A., Tatum, A.H., Newman, N.B., Gamble, G.P., Etzell, J.E., Weidner, N., Kern, J.A., Sorscher, S.M., Kohman, L.J. and Graziano, S.L. (1999) Prognostic markers in resected stage I and II non small-cell lung cancer: An analysis of 260 patients with 5 year follow-up. Clin. Lung Cancer, 1, 59-67; discussion 68-69.
16. Ahrendt, S.A., Hu, Y., Buta, N., McDermott, M.P., Benoit, N., Yang, S.C., Wu, L. and Sidransky, D. (2003) p53 mutations and survival in stage I non-small cell lung cancer: Results of a prospective study. J. Natl Cancer Inst., 95, 901-970.
17. Tan, D.F., Li, Q., Rammath, N., Beck, A., Wiseman, S., Anderson, T., al-Salameh, A., Brooks, J. and Bepler, G. (2003) Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer. Anticancer Res., 23, 1665-1672.
18. Grossi, F., Loprevite, M., Chiaramondia, M., Ceppa, P., Pera, C., Ratto, G.B., Serrano, J., Ferrara, G.B., Costa, R., Boni, L. and Ardizzoni, A. (2003) Prognostic significance of K-ras, p53, bcl-2. PCNA. CD34 in radically resected non-small cell lung cancers. Eur. J. Cancer. 39, 1242-1250.
19. Schiller, J.H., Adak. S., Feins, R.H. et al. (2001) Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J. Clin. Oncol., 19, 448-457.